A Phase I/II Clinical Study of Foritinib Succinate in Non-small Cell Lung Cancer (NSCLC) Patients

Conditions:   Advanced Cancer;   Advanced Solid Tumor;   Lung Cancer, Nonsmall Cell Intervention:   Drug: SAF-189 Sponsor:   Shanghai Fosun Pharmaceutical Development Co, Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

CONCLUSION: In decision-making between segmentectomy and lobectomy, adequate margins are required for the selection of segmentectomy, the most common of which is LUL trisegmentectomy. Technical challenges can be overcome with adequate training and simulation. Additional research could focus on the identification of factors associated with recurrence. PMID: 32097983 [PubMed - as supplied by publisher]
Source: Surgical Technology International - Category: Surgery Tags: Surg Technol Int Source Type: research
Conditions:   Metastatic Lung Non-Small Cell Carcinoma;   Refractory Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8 Interventions:   Biological: Necitumumab;   Drug: Osimertinib;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Biological: Trastuzumab Sponsors:   Jonsson Comprehensive Cancer&...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 26 February 2020Source: Respiratory InvestigationAuthor(s): Miho Tanaka, Tatsuya Ishii, Rie Tohnai, Shoichi Itoh, Yoshitaka Kawa, Yuko Kono, Yoshiko Urata, Yoshihiro Hattori, Miyako Satouchi
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
CONCLUSIONS: Our results indicated that HOXA-AS2 could enhance the migration and invasion abilities of NSCLC by targeting miR-145-3p. Furthermore, these findings suggested that HOXA-AS2 might be a potential therapeutic target for NSCLC. PMID: 32096154 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
CONCLUSIONS: LncRNA TRERNA1 was up-regulated both in NSCLC tissues and cell lines. Its level was associated with pathological stage and poor prognosis in NSCLC. In addition, lncRNA TRERNA1 could promote the malignant progression of NSCLC via modulating FOXL1. PMID: 32096153 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Conclusions: We found that recent recurrence, oligo-recurrence, and DLT were associated with an improved median PR-PFS time and long-term PR-PFS rate in patients with postoperative recurrence after complete resection of NSCLC. On the basis of these results, we believe that DLT should be considered first for patients with oligo-recurrence before applying noncurative treatment.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Thoracic Source Type: research
This article provides an overview of the current state of knowledge of the clinical experience using radiation therapy in combination with immune therapy and discusses the rationale for integrating these 2 modalities in the treatment of advanced non–small cell lung cancer. Available data supports the use of radiation therapy in combination with immunotherapy to achieve improved local and systemic tumor control. Evidence from the early clinical trials has shown that using radiation therapy and immune checkpoint blockade therapies together produces a greater clinical effect than using either modality alone. To maximize...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Review Article Source Type: research
(University of Pennsylvania School of Medicine) Non-small cell lung cancer (NSCLC) patients with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to PD-1-based immunotherapy treatments than patients with a lower measure of mutations.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Conclusion: Apatinib is an optional choice as salvage treatment in elderly patients with advanced metastatic NSCLC, with modest efficacy and acceptable toxicities.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conclusions: SBRT results in excellent local control (LC) and acceptable survival in medically inoperable ES-NSCLC with minimal adverse effects. Charlson comorbidity index and target volume are important prognostic factors and may aid in patient selection.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study